Conformation-specific nanobody targeting alpha-synuclein oligomers for neurodegeneration theragnostics
A nanobody that selectively binds the P1 region (residues 36–42) of alpha-synuclein, enabling specific targeting of toxic oligomeric self-assemblies implicated in Parkinson's and Alzheimer's disease. The nanobody inhibit...